CY1116439T1 - Τριαζολοπυριδινες - Google Patents

Τριαζολοπυριδινες

Info

Publication number
CY1116439T1
CY1116439T1 CY20151100512T CY151100512T CY1116439T1 CY 1116439 T1 CY1116439 T1 CY 1116439T1 CY 20151100512 T CY20151100512 T CY 20151100512T CY 151100512 T CY151100512 T CY 151100512T CY 1116439 T1 CY1116439 T1 CY 1116439T1
Authority
CY
Cyprus
Prior art keywords
compounds
triazolopyridines
prophylaxis
disease
preparing
Prior art date
Application number
CY20151100512T
Other languages
Greek (el)
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stöckigt
Philip Lienau
Hartmut Schirok
Hans Briem
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1116439T1 publication Critical patent/CY1116439T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20151100512T 2011-04-21 2015-06-12 Τριαζολοπυριδινες CY1116439T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27
EP12721779.2A EP2699575B1 (en) 2011-04-21 2012-04-16 Triazolopyridines

Publications (1)

Publication Number Publication Date
CY1116439T1 true CY1116439T1 (el) 2017-02-08

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100512T CY1116439T1 (el) 2011-04-21 2015-06-12 Τριαζολοπυριδινες

Country Status (39)

Country Link
US (1) US20140120087A1 (enExample)
EP (1) EP2699575B1 (enExample)
JP (1) JP5989091B2 (enExample)
KR (1) KR20140025470A (enExample)
CN (1) CN103608350B (enExample)
AP (1) AP3491A (enExample)
AR (1) AR086191A1 (enExample)
AU (1) AU2012244859B2 (enExample)
CA (1) CA2833657A1 (enExample)
CL (1) CL2013003044A1 (enExample)
CO (1) CO6801751A2 (enExample)
CR (1) CR20130539A (enExample)
CY (1) CY1116439T1 (enExample)
DK (1) DK2699575T3 (enExample)
DO (1) DOP2013000244A (enExample)
EA (1) EA023766B1 (enExample)
EC (1) ECSP13013011A (enExample)
ES (1) ES2539265T3 (enExample)
GT (1) GT201300254A (enExample)
HR (1) HRP20150517T1 (enExample)
HU (1) HUE025496T2 (enExample)
IL (1) IL228704A0 (enExample)
JO (1) JO3040B1 (enExample)
MA (1) MA35049B1 (enExample)
ME (1) ME02143B (enExample)
MX (1) MX348783B (enExample)
MY (1) MY164939A (enExample)
PE (1) PE20141351A1 (enExample)
PH (1) PH12013502169A1 (enExample)
PL (1) PL2699575T3 (enExample)
PT (1) PT2699575E (enExample)
RS (1) RS54044B1 (enExample)
SA (1) SA112330466B1 (enExample)
SG (1) SG194003A1 (enExample)
SI (1) SI2699575T1 (enExample)
TW (1) TWI558703B (enExample)
UY (1) UY34034A (enExample)
WO (1) WO2012143329A1 (enExample)
ZA (1) ZA201308707B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2872506A1 (en) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
JP2016520634A (ja) * 2013-06-07 2016-07-14 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CN105246891A (zh) * 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DE602005010876D1 (de) 2004-08-17 2008-12-18 Galderma Res & Dev Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
CA2662074A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR067562A1 (es) * 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
AU2008291075A1 (en) * 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201000797A1 (ru) * 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
JP2012517971A (ja) * 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての[1,2,4]トリアゾロ[1,5−a]ピリジン類
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
EA201301181A1 (ru) 2014-08-29
DK2699575T3 (da) 2015-06-22
CA2833657A1 (en) 2012-10-26
HRP20150517T1 (hr) 2015-06-19
PE20141351A1 (es) 2014-11-01
NZ616456A (en) 2015-09-25
RS54044B1 (sr) 2015-10-30
ES2539265T3 (es) 2015-06-29
MY164939A (en) 2018-02-15
TW201245194A (en) 2012-11-16
IL228704A0 (en) 2013-12-31
SG194003A1 (en) 2013-11-29
AU2012244859A1 (en) 2013-10-31
CN103608350B (zh) 2015-11-25
HUE025496T2 (en) 2016-04-28
AP2013007182A0 (en) 2013-10-31
ZA201308707B (en) 2016-07-27
PL2699575T3 (pl) 2015-08-31
HK1190398A1 (zh) 2014-07-04
ECSP13013011A (es) 2013-12-31
ME02143B (me) 2015-10-20
MX348783B (es) 2017-06-28
CO6801751A2 (es) 2013-11-29
SA112330466B1 (ar) 2015-09-28
EP2699575B1 (en) 2015-03-25
DOP2013000244A (es) 2014-03-16
AR086191A1 (es) 2013-11-27
JP2014511887A (ja) 2014-05-19
AU2012244859B2 (en) 2017-06-08
JO3040B1 (ar) 2016-09-05
MA35049B1 (fr) 2014-04-03
EA023766B1 (ru) 2016-07-29
WO2012143329A1 (en) 2012-10-26
KR20140025470A (ko) 2014-03-04
MX2013012289A (es) 2013-11-21
PH12013502169A1 (en) 2014-01-13
SI2699575T1 (sl) 2015-10-30
JP5989091B2 (ja) 2016-09-07
EP2699575A1 (en) 2014-02-26
CN103608350A (zh) 2014-02-26
PT2699575E (pt) 2015-07-29
CR20130539A (es) 2013-12-04
CL2013003044A1 (es) 2014-05-02
GT201300254A (es) 2015-09-01
AP3491A (en) 2015-12-31
UY34034A (es) 2012-11-30
US20140120087A1 (en) 2014-05-01
TWI558703B (zh) 2016-11-21

Similar Documents

Publication Publication Date Title
CY1116439T1 (el) Τριαζολοπυριδινες
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
CY1119433T1 (el) Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες
CY1120673T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1115866T1 (el) Τριαζολοπυριμιδινες
CY1117352T1 (el) Υποκατεστημενες ιμιδαζοπυριδαζiνες
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
CO6650348A2 (es) Triazolopiridinas sustituidas
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
CR20160016A (es) Pirazolpiridinas sustituidas
CY1117210T1 (el) Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης
EA201600394A1 (ru) Трициклические соединения пиперидина
BR112014009288A2 (pt) formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona